Article
作者: Hanley, Patrick W. ; Machado, Viviane ; Patel, Ami ; Frase, Drew ; Francica, Joseph R. ; Chokkalingam, Neethu ; Feldmann, Heinz ; Griffin, Amanda J. ; Choi, Jihae ; Feldmann, Friederike ; Parzych, Elizabeth M. ; Generotti, Allison ; Gary, Ebony N. ; Bharti, Suman ; Schouest, Blake ; Lovaglio, Jamie ; Smith, Trevor R. F. ; Esser, Mark T. ; Nguyen, Brian ; Smith, Brian J. ; Rosenke, Kyle ; Rosenthal, Kim ; Ali, Ali R. ; Lewis, Matt ; Kulkarni, Abhijeet ; Walker, Susanne N. ; Shaia, Carl ; Weiner, David B. ; Kulp, Daniel W.
COVID-19 remains a major public health concern. Monoclonal antibodies have received emergency use authorization (EUA) for pre-exposure prophylaxis against COVID-19 among high-risk groups for treatment of mild to moderate COVID-19. In addition to recombinant biologics, engineered synthetic DNA-encoded antibodies (DMAb) are an important strategy for direct in vivo delivery of protective mAb. A DMAb cocktail was synthetically engineered to encode the immunoglobulin heavy and light chains of two different two different Fc-engineered anti-SARS-CoV-2 antibodies. The DMAbs were designed to enhance in vivo expression and delivered intramuscularly to cynomolgus and rhesus macaques with a modified in vivo delivery regimen. Serum levels were detected in macaques, along with specific binding to SARS-CoV-2 spike receptor binding domain protein and neutralization of multiple SARS-CoV-2 variants of concern in pseudovirus and authentic live virus assays. Prophylactic administration was protective in rhesus macaques against signs of SARS-CoV-2 (USA-WA1/2020) associated disease in the lungs. Overall, the data support further study of DNA-encoded antibodies as an additional delivery mode for prevention of COVID-19 severe disease. These data have implications for human translation of gene-encoded mAbs for emerging infectious diseases and low dose mAb delivery against COVID-19.